Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: medsunman who wrote (13264)	1/13/1998 2:11:00 PM
From: Andrew H	Respond to of 32384

Thanks a lot!! Appreciate the report. Hard to imagine the leptin deal taking any longer, though (:>)

To: medsunman who wrote (13264)	1/13/1998 2:40:00 PM
From: bob smith	Read Replies (1) \| Respond to of 32384

medsunman, thanks for reporting. So why then are the big boys selling ? Last trade at $12.(at bid) 25000 shares Bob

To: medsunman who wrote (13264)	1/13/1998 2:43:00 PM
From: Henry Niman	Respond to of 32384

medsunman, Thanks for the update. It's about what I expected. Since LGND didn't issue any press releases, I expected today's talk to be an overall update on progress. Sounds like the leptin deal will be done very soon, or LGND will get another partner. I'm curious about the current "partner". It's my understanding that its a major pharma, and they are usually on the slow side, but this deal has to be setting some sort of record. Its only a research deal, and its hard to imagine why it would take this long. Hopefully, LGND has had some extensive talks with others, because this potential partner seems to less than ideal. Most of the summary that you posted is in line with (recent) expectations. I expect a series of revised estimates by analysts (similar to Bear Stearns which now also expects a profit next year), which hopefully will get the price moving north again. Any updates on clinicals or release of Phase II data for cancer or diabetes?

To: medsunman who wrote (13264)	1/13/1998 4:22:00 PM
From: squetch	Read Replies (1) \| Respond to of 32384

medsunman, Appreciate the update. Besides getting hosed, what was your impression of the presentations? I am confused about the profitability thing w/ the mkt share numbers. WHich is DR using to figure his profitability? The initial numbers, the growing to numbers, or somewhere in between? >>plus cash from warrants<< Is he talking about '00 or sooner? Thanks. Stan

To: medsunman who wrote (13264)	1/13/1998 6:07:00 PM
From: Russian Bear	Read Replies (3) \| Respond to of 32384

Thank you, Medsunman, for the update. Also, thanks to Bernie, via Henry. It all appears to be very good news, yet the stock languishes. I have a suspicion that the market is telling us something about the prospective LLY drug that Ligand has the option to aquire. It is just a hunch on my part, but I think they might pass, after all. This would result in (1) an increase of 1.5% on the royalties for Ligand's retinoid-of-choice, and (2) an additional $20 million placement of LGND stock to LLY. My supposition is that it is the second point that is weighing on the stock (an over-reaction; the "dilution" involved is insubstantial, in my opinion.) If this turns out to be the case, I, for one, will be thoroughly relieved (after getting over the shock of actually getting something right, for a change. ;-) The prospective drug that was discussed on the thread, some time ago, left me unimpressed, to say the least. Having said that, let me add that I trust the folks at Ligand to know their jobs a whole lot better than I do. And so, if they elect to take this LLY drug (or another one,) I will assume that it is the right call. Does anyone know anything substantive, on this front? RB

To: medsunman who wrote (13264)	1/14/1998 2:05:00 AM
From: Vector1	Read Replies (2) \| Respond to of 32384

Medsunman, Well done and accurate summary. In the breakout Robinson got to the heart of LGND's strategy. Get the products Targretin and Panretin) approved for a niche indication where the efficacy is compelling and then epand the use with ongoing studies and off label use. this is a classical oncology approach and a very sound business strategy for LGND. LGND is performing numerous mini phase II studies to see where the compounds are most active. On the negative side it is becomming clear that Neither Targretin nor panretin will be a major player in solid tumors. Moreover Panretin has been dropped from prostate cancer because of lack of activity. Targretin has shown activity and studies are continuing. On the whole I would describe the presentation as solid but not spectacular. There was no news on the LGND choice of LLY compound. The company also expressed a high level of confidence that they would achieve significant royalties from the PFE deals. V1

To: medsunman who wrote (13264)	1/14/1998 11:47:00 AM
From: HB	Respond to of 32384

Thanks. That statement on the Leptin deal suggests they are having trouble getting a deal they like. Maybe this is a reason for LGND's weakness. Back in @12 1/8. Howard